The Ministry of Health directorate that acts as Iraq's medicines regulator: it registers medicines and companies, keeps the national essential medicines list, sets registration prices, tests the quality of medicines and runs pharmacovigilance. A fast-track route introduced in 2019 relies on approvals by the FDA, EMA and other named regulators.
A 2021 report in the WHO's Eastern Mediterranean Health Journal, written by authors from the University of Baghdad, the Iraqi Pharmacovigilance Centre, the Minister's office and WHO, and based on the Iraq pharmaceutical country profile 2020, describes the Directorate of Technical Affairs as the main entity responsible for medicine regulation. Its Registration Department grants marketing authorisation to companies and products for the public and private sectors, sets registration prices (brand prices mainly by reference to Jordan, Saudi Arabia and the British National Formulary) and reviews registrations every five years. Its National Committee for Drug Selection, of 12 to 16 specialist physicians and pharmacists meeting usually weekly, selects medicines for the three-level national essential medicines list (1,105 medicines and vaccines, 554 of them at level 1, on 23 June 2020) and the comprehensive list (3,700 medicines), and asks for pharmacoeconomic studies before approving high-cost medicines such as biological and oncology medicines.
The Directorate recognises certificates from the FDA, EMA, WHO and the regulators of the United Kingdom, Switzerland, Canada, Australia, Japan and the Gulf Cooperation Council. Fast-track registration, introduced in February 2019, gives a product approved by one of these a temporary registration and import licence within a month on seven documents; the regular pathway takes about a year. Registered medicines rose from 2,500 in December 2018 to 4,665 in August 2020. Its National Centre for Drug Control and Research, founded in 1984, tests the quality of medicines before registration and before release, with companies that hold one of the recognised certificates exempt from batch testing, and the Iraqi Pharmacovigilance Centre, part of its Pharmacy Department, has been a member of the WHO Programme for International Drug Monitoring since 2010. The Kurdistan Region regulates medicines through its own agency, which requires the federal registration decision first. The coordinates are a Baghdad city point.
Shares KIMADIA, State Company for Marketing Drugs and Medical Appliances (Iraq), Iraqi Cancer Board (Ministry of Health, Iraq), Global oncology and access in low- and middle-income countries.
Shares Kurdistan Medical Control Agency (KMCA), Kurdistan Region of Iraq, Iraqi Cancer Board (Ministry of Health, Iraq).
Shares Kurdistan Medical Control Agency (KMCA), Kurdistan Region of Iraq, Iraqi Cancer Board (Ministry of Health, Iraq).
Shares World Health Organization Cancer Programme, Global oncology and access in low- and middle-income countries.
Shares World Health Organization Cancer Programme, Global oncology and access in low- and middle-income countries.
Shares World Health Organization Cancer Programme, Global oncology and access in low- and middle-income countries.
Shares World Health Organization Cancer Programme, Global oncology and access in low- and middle-income countries.
Shares World Health Organization Cancer Programme, Global oncology and access in low- and middle-income countries.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/